Skip to content
ChickenStockChickenStock
Research086450
Dongkook Pharmaceutical logo

Dongkook Pharmaceutical (086450) stock

KOSDAQ · Pharmaceuticals

KRW 22,050-7.74%(-1,850)

As of Nov 16, 1:11 PM KST

Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.

Price date for the multiples · Nov 16, 2026 · Financial period · Trailing twelve months

P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock

P/E

14.31x

P/B

1.47x

P/S

0.99x

Earnings

Revenue, operating profit and net income from periodic reports filed with DART, Korea’s regulatory filing system.

Quarters and year-to-date
PeriodRevenueOperating profitNet incomeRevenue YoY
Q2 2026Consolidated · Filed Aug 14, 2026KRW 258.9 billionKRW 26.1 billionKRW 17.2 billion+10.9%
Q1 2026Consolidated · Filed May 15, 2026KRW 251 billionKRW 27.3 billionKRW 26.3 billion+12.2%
Q4 2025Consolidated · Filed Mar 12, 2026KRW 242.9 billionKRW 24.3 billionKRW 15.6 billion—
Q3 2025Consolidated · Filed Nov 14, 2025KRW 226.8 billionKRW 24.8 billionKRW 22.3 billion+12.9%
Q2 2025Consolidated · Filed Aug 14, 2025KRW 233.5 billionKRW 22.1 billionKRW 18.1 billion+14.7%
Q1 2025Consolidated · Filed May 15, 2025KRW 223.7 billionKRW 25.3 billionKRW 18 billion+13.7%
Fiscal years
PeriodRevenueOperating profitNet incomeRevenue YoY
FY2025Consolidated · Filed Mar 12, 2026KRW 926.9 billionKRW 96.6 billionKRW 73.9 billion—
FY2024Consolidated · Filed Mar 13, 2025KRW 812.2 billionKRW 80.4 billionKRW 62.3 billion—
  • Q2 2026 is computed as H1 2026 minus Q1 2026.
  • Q4 2025 is computed as FY2025 minus 9M 2025.
  • Q3 2025 is computed as 9M 2025 minus H1 2025.
  • Q2 2025 is computed as H1 2025 minus Q1 2025.
Original filing (DART)

Short selling and securities lending

Short sales as a share of trading value, the reported short position and the securities lending balance.

Short-sale share
3.56%
Of trading value on Nov 13, 2026
Short-sale value
KRW 490 million
Previous 20-day average 4.78%
Net short position
163,435 shares
As of Nov 11, 2026 · reported with a two-trading-day lag
Lending balance
4,263,536 shares
As of Nov 13, 2026 · 9.43% of listed shares
Recent short-sale days
DateShareValue
Nov 13, 20263.56%KRW 490 million
Nov 12, 202610.26%KRW 1 billion
Nov 11, 20267.44%KRW 940 million
Nov 10, 20262.43%KRW 250 million
Nov 9, 20262.98%KRW 260 million
Nov 6, 20263.04%KRW 270 million
Nov 5, 20262.00%KRW 360 million
Nov 4, 20264.20%KRW 410 million
Nov 3, 20265.29%KRW 900 million
Nov 2, 20267.91%KRW 820 million

The short-sale share is short-sale value divided by total trading value that day. The lending balance also includes stock lent for purposes other than short selling.

Dongkook Pharmaceutical (086450) stock information

KOSDAQ

Dongkook Pharmaceutical (086450) is listed on KOSDAQ. Its market capitalization is about KRW 997.3 billion. On trailing-twelve-month earnings the P/E ratio is 14.31, and the P/B ratio is 1.47. Return on equity is 10.3%. These figures are computed in-house from official filings and are reference information only.

Dongkook Pharmaceutical — frequently asked questions

What is the P/E ratio of Dongkook Pharmaceutical (086450)?
On a trailing-twelve-month basis, 086450 trades at a P/E ratio of 14.31. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
What is the market capitalization of Dongkook Pharmaceutical?
086450 has a market capitalization of about KRW 997.3 billion. The figure moves with the share price and is refreshed each trading day.
Does Dongkook Pharmaceutical pay a dividend?
086450 has a dividend yield of about 0.91%, based on disclosed payment history. Dividend policy can change; this is reference information only.
Is this page investment advice?
No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.

All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.